Myriad Genetics Stock Soars 11.26% Despite Analyst Downgrades

Myriad Genetics' stock surged 11.26% in pre-market trading on April 15, 2025, marking a significant rise in investor interest and confidence in the company's prospects.

Myriad Genetics, a leading genetic testing and precision medicine company, has recently faced a series of analyst downgrades. Bank of America (BofA) lowered its price target for Myriad Genetics from $11 to $9, maintaining an Underperform rating. This adjustment reflects a cautious outlook on the company's future performance, potentially influencing investor sentiment and contributing to the recent stock price movements.

Despite the downgrades, Myriad Genetics continues to focus on its core strengths in genetic testing and precision medicine. The company's dedication to advancing health and well-being through innovative solutions remains a key driver of its long-term strategy. Recent financial results, including those for the fourth quarter and full-year ended December 31, 2024, provide insights into the company's operational performance and financial health.